Company / Cash per Share
TScan Therapeutics, Inc. Cash per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$1.36
FY2025
5-year range
$1.36 / $176.20
FY2021-FY2025
Trend
-50.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash per Share has declined for 4 consecutive years, from $176.20 in FY2021 to $1.36 in FY2025.
Based on SEC 10-K filings.
1.36 in FY2025 with a 3-year CAGR of -49.1%.
Declined from $5.55 to $1.36 over the past 2 years.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -49.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- TScan Therapeutics, Inc.'s cash per share has declined for 4 consecutive years.
- In FY2025, cash per share decreased 50.0% year-over-year.
- Peak cash per share was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.36 | -50.0% |
| FY2024 | $2.72 | -50.9% |
| FY2023 | $5.55 | -46.1% |
| FY2022 | $10.29 | -94.2% |
| FY2021 | $176.20 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026